Investor Relations
Stock Information
| Ticker |
SNTS |
| Exchange |
NASDAQ |
| Price |
$2.25 |
| Change |
- 0.04 |
| Volume |
155,900 |
| Sep 2, 2010 4:00 PM ET |
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians. The company's current commercial efforts are focused on GLUMETZA® (metformin HCl extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Santarus is also developing two late-stage lower gastrointestinal product candidates, budesonide MMX® and rifamycin SV MMX®, for the U.S. market. Budesonide MMX is being investigated in a Phase III clinical program for the induction of remission of mild or moderate active ulcerative colitis. Santarus began Phase III clinical testing of rifamycin SV MMX in patients with travelers' diarrhea in the second quarter of 2010.
